572.4K XNAS Volume
XNAS 17 Mar, 2025 5:30 PM (EDT)
Board Meeting
The board meeting for Compass Pathways Plc - ADR is scheduled for today, for the purpose of Stifel Virtual CNS Forum
See details
Compass Pathways Plc - ADR Key Metrics
Default
All financials are in USD Million and price data in USD
VIEW MORE
Not Eligible
Expensive Valuation
Technically Bearish
Check Before You Buy
VIEW FULL CHECKLISTLow rank
3Positive16Negative
15.8% Pass in checklist
Check P/E Buy Sell Zone
This stock has negative PE
Compass Pathways Plc - ADR Stock Price Analysis
Day Price Range | 3.5 (LTP) 3.43.5 LowHigh |
Week Price Range | 3.5 (LTP) 3.43.8 LowHigh |
Month Price Range | 3.5 (LTP) 3.44.9 LowHigh |
52 Week Price Range | 3.5 (LTP) 3.210.3 LowHigh |
Compass Pathways Plc - ADR Live Price Chart
Switch to TradingView
Fetching data ...
Revenue forecast
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get Compass Pathways Plc - ADR Stock Analysis
Compass Pathways Plc - ADR stock analysis with key metrics, changes, and trends.
Compass Pathways Plc - ADR Metric | VALUE | CHANGE % | TREND | ANALYSIS | |
---|---|---|---|---|---|
Annual Net Profit | $155.12 M | 30.94% | negative |
| |
Price to Earning Ratio | -2.07 | - | negative |
| |
Stock Price | $3.46 | -65.05% | negative |
| |
Quarterly Net profit | $43.33 M | 33.2% | negative |
| |
Debt to Equity Ratio | 0.21 | - | positive |
| |
Return on Equity(ROE) | -81.55 % | -81.55% | negative |
| |
Mutual Fund Holding | 5.51 % | -0.53% | negative |
| |
Interest Coverage Ratio | -33.28 | - | negative |
| |
Institutional Holding | 33.57 % | 0% | neutral |
|
Loading data..
Compass Pathways Plc - ADR - Company Profile
What does Compass Pathways Plc - ADR do?
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Compass Pathways Plc - ADR Management structure
All Gross Remunerations are in USD
Compass Pathways Plc - ADR Board of directors
All Gross Remunerations are in USD